Texas Instruments R&D decreased by 2.1% to $510.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.4%, from $517.00M to $510.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 7.6% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $391.00M | $388.00M | $389.00M | $391.00M | $414.00M | $431.00M | $434.00M | $455.00M | $477.00M | $471.00M | $460.00M | $478.00M | $498.00M | $492.00M | $491.00M | $517.00M | $527.00M | $518.00M | $521.00M | $510.00M |
| QoQ Change | — | -0.8% | +0.3% | +0.5% | +5.9% | +4.1% | +0.7% | +4.8% | +4.8% | -1.3% | -2.3% | +3.9% | +4.2% | -1.2% | -0.2% | +5.3% | +1.9% | -1.7% | +0.6% | -2.1% |
| YoY Change | — | — | — | — | +5.9% | +11.1% | +11.6% | +16.4% | +15.2% | +9.3% | +6.0% | +5.1% | +4.4% | +4.5% | +6.7% | +8.2% | +5.8% | +5.3% | +6.1% | -1.4% |
| Segment | Q1 '25 | Q1 '26 |
|---|---|---|
| Analog | $369.00M | $369.00M |
| Embedded Processing | $128.00M | $123.00M |
| Other | $20.00M | $18.00M |
| Total | $517.00M | $510.00M |